USPTO serial 99536121
Reviewed by CopyMark Law Group
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Katherine P. Califa
Katherine P. Califa Foley & Lardner LLP3000 K Street, N.W.Sixth FloorWashington, DC 20007| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Radiopharmaceutical and radioisotope preparations for clinical, medical, medical diagnostic and therapeutic use | ACTIVE | — |
| 035 | Distributorship services in the field of radiopharmaceuticals; distributorship services featuring pharmaceuticals, radiopharmaceuticals, and nuclear medicine products; business management and logistics management in the field of radiopharmaceuticals; supply chain management for pharmaceutical and radiopharmaceutical products; business administration and consulting services for radiopharmaceutical and radiopharmacy operations; Regulatory submission management services, namely, assisting others in preparing and filing applications for radiopharmaceuticals with governmental regulatory bodies | ACTIVE | — |
| 039 | Supply chain and logistics services, namely, transportation, delivery, distribution in the nature of delivery, and storage of radiopharmaceuticals and radioisotopes; consultation and coordination services being the transport and storage of radiopharmaceuticals and radioisotopes | ACTIVE | — |
| 040 | Isotope production being the manufacture of isotopes for products being sold to others for medical, research, and commercial use; contract manufacturing services in the field of pharmaceuticals and radiopharmaceuticals; Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials; Manufacturing services for others in the field of pharmaceuticals and radiopharmaceuticals; Custom manufacture of pharmaceuticals | ACTIVE | — |
| 042 | Laboratory testing, quality control, and validation services for radiopharmaceuticals; process development, optimization, and scale-up services in the field of radiopharmaceutical manufacturing, namely developing and scaling manufacturing processes for radiopharmaceuticals, pharmaceuticals, and nuclear medicine products for others; technological consultancy relating to radiopharmaceutical production and regulatory compliance; Pharmaceutical drug development services; Laboratory services for the production of radiopharmaceuticals in the nature of research and development of new products and testing of pharmaceuticals; Quality control for others; Scientific and technological services namely, research in the field of radiochemistry, radiopharmaceuticals, and nuclear medicine; contract manufacturing services in the field of pharmaceuticals and radiopharmaceuticals | ACTIVE | — |
| 044 | radiopharmacy services, namely, preparation and dispensing of radiopharmaceuticals for diagnostic and therapeutic purposes; consultation and clinical support services related to the preparation and administration of radiopharmaceuticals and radioisotopes | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 25, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 25, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 25, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 24, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 24, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 24, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 10, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jul 10, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Apr 13, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 13, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 8, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 8, 2025 | NWAP | NEW APPLICATION ENTERED | — |